Fosun Pharma subsidiary gets approval for Foscarnet Sodium Injection

Shanghai Fosun Pharmaceutical Group (Fosun Pharma) announced that its controlled subsidiary, Guilin Pharmaceutical Co., Ltd., has received registration approval from the National Medical Products Administration for Foscarnet Sodium Injection. The approved indications for the drug are the treatment of cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus mucocutaneous infections in immunocompromised patients.

As of November 2025, Fosun Pharma and its subsidiaries have invested approximately RMB 4.98 million (unaudited) in the research and development of this drug. According to IQVIA CHPA data, sales of Foscarnet Sodium Injection in mainland China amounted to approximately RMB 86.40 million in 2024.

This approval is expected to enrich Fosun Pharma's product line. However, the company cautioned that actual sales performance post-launch might be affected by factors such as treatment demand, market competition, and sales channels, indicating inherent uncertainties in market success.